Volume 4, Issue 1 (Winter 2018)                   Caspian.J.Neurol.Sci 2018, 4(1): 1-5 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadianinejad S, Majidinasab N, Nejati A, Hatamian H, Mehramiri A, Sajedi S et al . Tapering Oral Steroid Treatment After IV Methylprednisolone Pulse Therapy in Demyelinating Optic Neuritis. Caspian.J.Neurol.Sci 2018; 4 (1) :1-5
URL: http://cjns.gums.ac.ir/article-1-212-en.html
1- Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran , nejatiadel@gmail.com
3- Department of Neurology, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Abstract:   (3195 Views)
Background: Optic neuritis is an inflammation of the optic nerve. Because of importance of vision for human, management of optic neuritis is an important issue in neurology.
Objectives: This study aimed at assessing the effect of oral steroid treatment after intravenous (IV) methylprednisolone therapy on demyelinating optic neuritis.
Materials & Methods: 60 Patients with first episode of acute demyelinating optic neuritis who referred to a neurology clinic in an academic hospital in south-west of Iran in 2015-2016 included in this randomized double-blind clinical trial study (No: IRCT2015102724735N1). They were divided into two groups with (A) and without (B) tapering oral steroid treatment after IV methylprednisolone. Visual acuity and color vision were measured before treatment, before oral tapering, 1 and 3 months after treatment. Independent t-test in SPSS software version 20 was used to analyze the data. P<0.05 was considered as the level of significance.
Results: Visual acuity in two groups did not have any significant difference in any time point of assessment (P>0.05).Frequency of color vision abnormality in groups A and B were at baseline (53.3% vs. 56.6%) (P=0.796), before oral tapering (43.3% vs. 30%, P=0.284), 1 month after treatment (23.3% vs. 30%, P=0.559), 3 months after treatment (0% vs. 23%, P=0.011). 
Conclusion: Oral steroid treatment after IV methylprednisolone pulse therapy improves color vision after 3 months in patients with demyelinating optic neuritis but has no effect on visual acuity.
Full-Text [PDF 827 kb]   (3546 Downloads) |   |   Full-Text (HTML)  (1609 Views)  
Type of Study: Research | Subject: Special
Received: 2016/11/20 | Accepted: 2017/03/3 | Published: 2018/01/1

1. Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004; 61(9):1386-9. doi: 10.1001/archneur.61.9.1386 [DOI:10.1001/archneur.61.9.1386]
2. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003; 121(7):944-9. doi: 10.1001/archopht.121.7.944 [DOI:10.1001/archopht.121.7.944]
3. Atkins EJ, Biousse V, Newman NJ. The natural history of optic neuritis. Rev Neurol Dis. 2006; 3(2):45-6. PMID: 16819420 [PMID]
4. Flanagan P, Zele AJ. Chromatic and luminance losses with multiple sclerosis and optic neuritis measured using dynamic random luminance contrast noise. Ophthalmic Physiol Opt. 2004; 24(3):225–33. doi: 10.1111/j.1475-1313.2004.00191.x [DOI:10.1111/j.1475-1313.2004.00191.x]
5. Levin LA, Lessell S. Optic neuritis and Multiple Sclerosis. Arch Ophthalmol. 2003; 121(7):1039-4. doi: 10.1001/archopht.121.7.1039 [DOI:10.1001/archopht.121.7.1039]
6. Levin LA. Risk of Multiple Sclerosis after optic neuritis. JAMA. 2003; 290(3):403-4. doi: 10.1001/jama.290.3.403 [DOI:10.1001/jama.290.3.403]
7. Osborne BJ, Volpe NJ. Optic Neuritis and Risk of MS: Differential Diagnosis and Management. Cleve Clin J Med. 2009; 76(3):181-90. doi: 10.3949/ccjm.76a.07268 [DOI:10.3949/ccjm.76a.07268]
8. Warner JEA. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis? Arch Ophthalmol. 1997; 115(11):1408. PMID: 9366671 [DOI:10.1001/archopht.1997.01100160578009] [PMID]
9. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4):473–7. doi: 10.1084/jem.20050304 [DOI:10.1084/jem.20050304]
10. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from Multiple Sclerosis. Lancet. 2004; 364(9451):2106–12. doi: 10.1016/s0140-6736(04)17551-x [DOI:10.1016/S0140-6736(04)17551-X]
11. Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, et al. Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol Case Rep. 2004; 137(1):77–83. PMID: 14700647 [DOI:10.1016/S0002-9394(03)00862-6]
12. Bee YS, Lin MC, Wang CC, Sheu SJ. Optic Neuritis: Clinical Analysis of 27 Cases. Gaoxiong Yi Xue Ke Xue Za Zhi. 2003; 19(3):105–11. doi: 10.1016/s1607-551x(09)70457-7 [DOI:10.1016/S1607-551X(09)70457-7]
13. Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite Multiple Sclerosis. Arch Neurol. 2004; 61(10):1538-41. doi: 10.1001/archneur.61.10.1538 [DOI:10.1001/archneur.61.10.1538]
14. Optic Neuritis Study Group. The clinical profile of optic neuritis. Arch Ophthalmol. 1991; 109(12):1673-78. doi: 10.1001/archopht.1991.01080120057025 [DOI:10.1001/archopht.1991.01080120057025]
15. Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1999; 106(11):2047–53. doi: 10.1016/s0161-6420(99)90482-7 [DOI:10.1016/S0161-6420(99)90482-7]
16. Arnold AC. Evolving management of optic neuritis and Multiple Sclerosis. Am J Ophthalmol Case Rep. 2005; 139(6):1101–8. doi: 10.1016/j.ajo.2005.01.031 [DOI:10.1016/j.ajo.2005.01.031]
17. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006; 40(7-8):1261–6. doi: 10.1345/aph.1g703 [DOI:10.1345/aph.1G703]
18. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992; 326(9):581-8. doi: 10.1056/NEJM199202273260901 [DOI:10.1056/NEJM199202273260901]
19. Mehrotra A, Saxena R, Jaffery N, Menon V. Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis. Indian J Ophthalmol. 2007; 55(5):355-9. doi: 10.4103/0301-4738.33821 [DOI:10.4103/0301-4738.33821]
20. Optic Neuritis Study Group. The clinical profile of optic neuritis. Arch Ophthalmol. 1991; 109(12):1673-1678. doi: 10.1001/archopht.1991.01080120057025 [DOI:10.1001/archopht.1991.01080120057025]
21. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA. 1993; 269(16):2110-2.PMID: 8468765 https://doi.org/10.1001/jama.269.16.2110 [DOI:10.1001/jama.1993.03500160080036] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Caspian Journal of Neurological Sciences

Designed & Developed by : Yektaweb